Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Breast Cancer | Research article

Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?

Authors: Florian Ebner, Achim Wöckel, Lukas Schwentner, Maria Blettner, Wolfgang Janni, Rolf Kreienberg, Manfred Wischnewsky

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

The decision making process for axillary dissection has changed in recent years for patients with early breast cancer and positive sentinel lymph nodes (LN). The question now arises, what is the optimal surgical treatment for patients with positive axillary LN (pN+). This article tries to answer the following questions:
(1)
Is there a survival benefit for breast cancer patients with 3 or more positive LN (pN3+) and with more than 10 removed LN?
 
(2)
Is there a survival benefit for high risk breast cancer patients (triple negative or Her2 + breast cancer) and with 3 or more positive LN (pN3+) with more than 10 removed LN?
 
(3)
In pN + patients is the prognostic value of the lymph node ratio (LNR) of pN+/pN removed impaired if 10 or less LN are removed?
 

Methods

A retrospective database analysis of the multi center cohort database BRENDA (breast cancer under evidence based guidelines) with data from 9625 patients from 17 breast centers was carried out. Guideline adherence was defined by the 2008 German National consensus guidelines.

Results

2992 out of 9625 patients had histological confirmed positive lymph nodes. The most important factors for survival were intrinsic sub types, tumor size and guideline adherent chemo- and hormonal treatment (and age at diagnosis for overall survival (OAS)). Uni-and multivariable analyses for recurrence free survival (RFS) and OAS showed no significant survival benefit when removing more than 10 lymph nodes even for high-risk patients. The mean and median of LNR were significantly higher in the pN+ patients with ≤10 excised LN compared to patients with > 10 excised LN. LNR was in both, uni-and multivariable, analysis a highly significant prognostic factor for RFS and OAS in both subgroups of pN + patients with less respective more than 10 excised LN. Multivariable COX regression analysis was adjusted by age, tumor size, intrinsic sub types and guideline adherent adjuvant systemic therapy.

Conclusion

The removal of more than 10 LN did not result in a significant survival benefit even in high risk pN + breast cancer patients.
Literature
1.
Kreienberg R, Kopp I, Albert U, Al E. Interdisciplinary S3 guideline for diagnosis and therapy of breast cancer in women. Ger Cancer Soc. 2008.
2.
Soares EWS, Nagai HM, Bredt LC, da Cunha AD, Andrade RJ, Soares GVS. Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients. World J Surg Oncol. 2014;12:67.CrossRef
3.
Javid SH, He H, Korde LA, Flum DR, Anderson BO. Predictors and outcomes of completion axillary node dissection among older breast cancer patients. Ann Surg Oncol. 2014;21(7):2172–80.CrossRef
4.
Glechner A, Wöckel A, Gartlehner G, Thaler K, Strobelberger M, Griebler U, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013;49(4):812–25.CrossRef
5.
Janni W, Kühn T, Schwentner L, Kreienberg R, Fehm T, Wöckel A. Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits. Dtsch Arztebl Int. 2014;111(14):244–9.PubMedPubMedCentral
6.
Ebner F, Wöckel A, Janni W, Kreienberg R, Schwentner L, Wischnewsky M. Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival. J Cancer Res Clin Oncol. 2017;143(9):1–9.CrossRef
7.
NCCN. NCCN clinical practice guidelines in oncology (NCCN guidelines ® ) breast Cancer version 2.2018 [internet] (2018).
8.
Leitlinienprogramm der (Deutsche Krebsgesellschaft; Deutsche Krebshilfe; AWMF). S3 - Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms. AWMF Registernummer: 032 - 045OL (2018).
9.
Yan M, Abdi MA, Falkson C. Axillary Management in Breast Cancer Patients: a comprehensive review of the key trials. Clin Breast Cancer. 2018;18(6):e1251–9.CrossRef
10.
Ebner F, Hancke K, Blettner M, Schwentner L, Wöckel A, Kreienberg R, et al. Aggressive intrinsic subtypes in breast cancer: a predictor of guideline adherence in older patients with breast cancer? Clin Breast Cancer. 2015;15(4):e189–95.CrossRef
11.
Wolters R, Ebner F, Janni W, Novopashenny I, Wöckel A, Kreienberg R, et al. Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients. Arch Gynecol Obstet. 2016;294(2):377–84.CrossRef
12.
Schwentner L, Wöckel A, König J, Janni W, Ebner F, Blettner M, et al. Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9,156 patients. BMC Cancer. 2013;13:487.CrossRef
13.
Wöckel A, Kurzeder C, Geyer V, Novasphenny I, Wolters R, Wischnewsky M, et al. Effects of guideline adherence in primary breast cancer-a 5-year multi-center cohort study of 3976 patients. Breast. 2010;19(2):120–7.CrossRef
14.
Schwentner L, Dayan D, Wöckel A, Janni W, Kreienberg R, Blettner M, et al. Is extracapsular nodal extension in sentinel nodes a predictor for nonsentinel metastasis and is there an impact on survival parameters?-a retrospective single center cohort study with 324 patients. Breast J. 2018;24(4):480–6.CrossRef
15.
Wöckel A, Wolters R, Wiegel T, Novopashenny I, Janni W, Kreienberg R, et al. The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects. Ann Oncol. 2014;25(3):628–32.CrossRef
16.
Wolters R, Regierer AC, Schwentner L, Geyer V, Possinger K, Kreienberg R, et al. A comparison of international breast cancer guidelines - do the national guidelines differ in treatment recommendations? Eur J Cancer. 2012;48(1):1–11.CrossRef
17.
Liao G-S, Chou Y-C, Hsu H-M, Dai M-S, Yu J-C. The prognostic value of lymph node status among breast cancer subtypes. Am J Surg. 2015;209(4):717–24.CrossRef
18.
Chang Y-J, Chung K-P, Chen L-J, Chang Y-J. Ratio and log odds of positive lymph nodes in breast Cancer patients with mastectomy. Surg Oncol. 2015;24(3):239–47.CrossRef
19.
Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(18):2946–53.CrossRef
20.
Bromham N, Astin M, Hasler E, Mw R, Bromham N, Schmidt-hansen M, et al. Axillary treatment for operable primary breast cancer ( review ) axillary treatment for operable primary breast cancer. Cochrane database Syst rev. 2017;4(1):cd004561.
21.
Sanghani M, Balk EM, Cady B. Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients: a systematic review and meta-analysis. Cancer. 2009;115(8):1613–20.CrossRef
22.
Zhang P-Z, Chong L, Zhao Y, Gu J, Tian J-H, Yang K-H. Is axillary dissection necessary for breast cancer in old women? A meta-analysis of randomized clinical trials. Asian Pac J Cancer Prev. 2013;14(2):947–50.CrossRef
23.
Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast Cancer: a systematic review. JAMA. 2013;310(13):1385–94.CrossRef
24.
Martelli G, Boracchi P, Orenti A, Lozza L, Maugeri I, Vetrella G, et al. Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-year results of trial and out-trial patients. Eur J Surg Oncol. 2014;40(7):805–12.CrossRef
25.
Bonneau C, Hequet D, Estevez JP, Pouget N, Rouzier R. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes. Eur J Surg Oncol. 2015;41(8):998–1004.CrossRef
26.
Li CZ, Zhang P, Li RW, Wu CT, Zhang XP, Zhu HC. Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis: a meta-analysis. Eur J Surg Oncol. 2015;41(8):958–66.CrossRef
27.
Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.CrossRef
28.
Sávolt Á, Polgár C, Musonda P, Mátrai Z, Rényi-Vámos F, Tóth L, et al. Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node–positive patients? Clin Breast Cancer. 2013;13(5):364–70.CrossRef
29.
Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla – surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer. Eur J Surg Oncol. 2017;43(4):672–9.CrossRef
30.
Yao K, Liederbach E, Pesce C, Wang C-H, Winchester DJ. Impact of the American College of Surgeons oncology group Z0011 randomized trial on the number of axillary nodes removed for patients with early-stage breast Cancer. J Am Coll Surg. 2015;221(1):71–81.CrossRef
31.
de Gregorio A, Widschwendter P, Albrecht S, de Gregorio N, Friedl TWP, Huober J, et al. Axillary surgery in breast Cancer patients treated with breast-conserving surgery at German breast Cancer centers within the last 14 years - comparison of a Unversity center and a community hospital. Geburtsh Frauenheilk. 2018;78:1–8.CrossRef
32.
Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7.CrossRef
33.
Kreienberg R, Wöckel A, Wischnewsky M. Highly significant improvement in guideline adherence, relapse-free and overall survival in breast cancer patients when treated at certified breast cancer centres: an evaluation of 8323 patients. The breast. 2018;40:54–9.CrossRef
34.
Wollschläger D, Meng X, Wöckel A, Janni W, Kreienberg R, Blettner M, et al. Comorbidity-dependent adherence to guidelines and survival in breast cancer-is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients. Breast J. 2017;24(2):120–7.CrossRef
35.
Black D. Axillary ultrasound: for all, for none, to diagnose positive nodes, or to support avoiding sentinel lymph node biopsy altogether. Ann Surg Oncol. 2017;24(1):64–9.CrossRef
36.
Sackey H, Magnuson A, Sandelin K, Liljegren G, Bergkvist L, Fülep Z, et al. Arm lymphoedema after axillary surgery in women with invasive breast cancer. Br J Surg. 2014;101(4):390–7.CrossRef
37.
Jayasinghe UW, Pathmanathan N, Elder E, Boyages J. Prognostic value of the lymph node ratio for lymph-node-positive breast cancer- is it just a denominator problem? Springerplus. 2015;4:121.CrossRef
38.
Wu S-G, Sun J-Y, Zhou J, Li F-Y, Lin Q, Lin H-X, et al. Number of negative lymph nodes is associated with disease-free survival in patients with breast cancer. BMC Cancer. 2015;15:43.CrossRef
39.
Wu S-G, Wang Y, Zhou J, Sun J-Y, Li F-Y, Lin H-X, et al. Number of negative lymph nodes should be considered for incorporation into staging for breast cancer. Am J Cancer Res. 2015;5(2):844–53.PubMedPubMedCentral
40.
Wen J, Ye F, He X, Li S, Huang X, Xiao X, et al. Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer. Oncotarget. 2016;7(15):21046–53.CrossRef
41.
Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker S, Dall P, et al. Initial treatment of patients with primary breast Cancer: evidence, controversies, consensus. Geburtshilfe Frauenheilkd. 2017;77(6):633–44.CrossRef
42.
Witucki G, Degregorio N, Rempen A, Schwentner L, Bottke D, Janni W, et al. Evaluation of sentinel lymph node dose distribution in 3D conformal radiotherapy techniques in 67 pN0 breast Cancer patients. Int J Breast Cancer. 2015;2015:539842.CrossRef
43.
Zhao M, Liu W-G, Zhang L, Jin Z-N, Li Z, Liu C, et al. Can axillary radiotherapy replace axillary dissection for patients with positive sentinel nodes? A systematic review and meta-analysis. Chronic Dis Transl Med. 2017;3(1):41–50.CrossRef
44.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.CrossRef
45.
Schwentner L, Wolters R, Koretz K, Wischnewsky MB, Kreienberg R, Rottscholl R, et al. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-Centre cohort study. Breast Cancer Res Treat. 2012;132(3):1073–80.CrossRef
46.
Liang S, Hallet J, Simpson JS, Tricco AC, Scheer AS. Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: a systematic review and meta-analysis. J Geriatr Oncol. 2017;8(2):140–7.CrossRef
47.
Joyce DP, Manning A, Carter M, Hill ADK, Kell MR, Barry M. Meta-analysis to determine the clinical impact of axillary lymph node dissection in the treatment of invasive breast cancer. Breast Cancer Res Treat. 2015;153(2):235–40.CrossRef
48.
Ebner F, Friedl TWP, de Gregorio A, Lato K, Bekes I, Janni W, et al. Seroma in breast surgery: all the surgeons fault? Arch Gynecol Obstet. 2018;298(5):951–9.CrossRef
Metadata
Title
Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?
Authors
Florian Ebner
Achim Wöckel
Lukas Schwentner
Maria Blettner
Wolfgang Janni
Rolf Kreienberg
Manfred Wischnewsky
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5292-2

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Geospatial analyses identify regional hot spots of diffuse gastric cancer in rural Central America

Research article

Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors

Research article

Synergism of wt-p53 and synthetic material in local nano-TAE gene therapy of hepatoma: comparison of four systems and the possible mechanism

Research article

Stromal cell ratio based on automated image analysis as a predictor for platinum-resistant recurrent ovarian cancer

Study protocol

A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9–11 year-old girls and boys – clinical protocol

Research article

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits